Johnson & Johnson (NYSE:JNJ) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price is back in rally mode. It is still early in the game, but the Q2 results ...

Discover Johnson & Johnson's Q2 2025 earnings insights with raised guidance and strategic growth in Oncology & MedTech.

The FDA has placed pediatric ventricular assist bypass devices (product code DSQ) on its medical device shortage list.

Key Points Adjusted EPS reached $2.77 in Q2, topping estimates by $0.09, but fell year over year. Revenue rose 5.8% year over year to $23.7 billion, exceeding estimates by $889 million. Full-year 2025 ...

Medtronic (NYSE: MDT) today announced the first patient enrolled in the PELE trial of its Onyx liquid embolic system (LES).

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. BTIG analyst Ryan ...

DATEWednesday, July 16, 2025 at 8:30 a.m. ETCALL PARTICIPANTSChairman and Chief Executive Officer — Joaquin DuatoChief ...

Momentum in Johnson & Johnson’s cardiovascular business continues, while the company looks to regain its footing in the ...